Aslan turns focus to biliary tract cancer as lead drug flops in PhII gastric cancer study
About a year after securing the full rights to develop and commercialize varlitinib from Array BioPharma $ARRY, Aslan Pharma $ALSN said the drug failed …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.